Remove Biosimilars Remove Marketing Remove Therapies
article thumbnail

Bio-Techne Joins Forces with USP to Speed Up Development of mAbs and Gene Therapies

The Pharma Data

This alliance aims to address mounting challenges in the development and commercialization of mAb therapies and gene therapies, particularly those involving AAV vectors. To date, more than 160 monoclonal antibody therapies targeting nearly 100 disease-related proteins have received regulatory approval globally.

article thumbnail

Analyzing biosimilar market dynamics in different patient populations

Drug Patent Watch

Biosimilars have emerged as a game-changing force, promising to revolutionize patient access to life-saving biologics while simultaneously reducing healthcare costs. ”[1] The global biosimilars market is experiencing exponential growth, with projections indicating it will reach $69.4 from 2020 to 2025[1].

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Sunshine Biopharma Launches NIOPEG® into $10B Biologics Market

The Pharma Data

Sunshine Biopharma Launches NIOPEG® Biosimilar in Canada, Targeting $10B Biologics Market Sunshine Biopharma Inc. and marks Sunshine Biopharma’s entry into the rapidly expanding global biologics and biosimilars market. The global market for NEULASTA® and its biosimilars is substantial.

article thumbnail

The MAHA Assessment’s Implications: Drugs (Part One)

FDA Law Blog: Biosimilars

Therapies for chronic diseases, even in pediatrics, are not approved based on decades-long studies, and this is not likely to change. Similarly, FDA can use post-marketing requirements (PMRs). Notably, many of the issues regarding drugs are typically considered the practice of medicine, which FDA does not regulate.

Drugs 59
article thumbnail

Building the requisite clinical development infrastructure for medical innovation to thrive

Drug Target Review

They wait for the therapies that could significantly improve their quality of life or even save it knowing approval could be years or decades away. We are at a pivotal moment where we must consider how to improve these systems and ways of working to ensure critical therapies reach those who need them most.

article thumbnail

Pharma Contract Sales Outlook 2025–2030: Multilingual Teams Drive Global Expansion

The Pharma Data

Global Pharmaceutical Contract Sales Outsourcing Market to Reach $24.8 Billion by 2030: Strategic Insights, Regional Trends, and Technological Shifts Reshaping the Landscape The global pharmaceutical contract sales outsourcing (CSO) market is entering a transformative phase, with its value expected to grow from $17.3 In the U.S.,

article thumbnail

Business Leaders Review - The Heart and Strategy Behind Altasciences' Marketing Evolution

Alta Sciences

MENU logo-altasciences EN - Main navigation Proactive Drug Development Solutions Compare Us Facilities About Us Resource Center Careers News & Events 30th Anniversary Celebration Contact Us Participate in a study Français Home Current: Business Leaders Review - The Heart and Strategy Behind Altasciences' Marketing Evolution Business Leaders (..)